Tesamorelin / Ipamorelin is strictly for laboratory research and is commonly employed in the following investigational areas:

Metabolic Regulation and Lipodystrophy

Research models utilize this peptide combination to evaluate its effects on endogenous GH pulsatility and insulin sensitivity. Investigations focus on assessing its efficacy in visceral fat reduction and the associated improvement of liver enzymes, particularly in models of HIV-associated lipodystrophy.

Musculoskeletal Homeostasis and Remodeling

Experimental protocols employ these secretagogues to characterize their impact on body composition. Studies assess the ability of the peptides to decrease muscle fat and increase muscle area, as well as quantify their capacity to increase bone mineral content and counteract glucocorticoid-induced decreases in bone formation.

Gastrointestinal Motility

In gastroenterological research, ghrelin mimetics like Ipamorelin are used to study their selective stimulatory effects on the gastrointestinal tract. Researchers evaluate their efficacy in accelerating transit times in rodent models of postoperative ileus.

Pathway / Mechanistic Context

The primary mechanism of action for the Tesamorelin / Ipamorelin combination in research settings involves the synergistic dual-pathway activation of the somatotropic axis.

• GHRH Receptor Activation: Tesamorelin binds to the GHRH receptor on anterior pituitary cells, stimulating the synthesis and pulsatile release of natural growth hormone.
• GHSR-1a Receptor Activation: Ipamorelin mimics the endogenous ligand ghrelin by binding specifically to the growth hormone secretagogue receptor, further amplifying the GH pulse and actively suppressing somatostatin release.
• Synergistic GH Pulsatility: The combined action results in a robust, amplified release of endogenous growth hormone, driving targeted downstream effects such as IGF-1 production, lipolysis, and osteoblast stimulation.

Preclinical Research Summary

Published preclinical and clinical-translational literature documents the extensive investigation of Tesamorelin and Ipamorelin across diverse metabolic and musculoskeletal models.

• In lipodystrophy models, Tesamorelin demonstrated significant reductions in visceral adipose tissue, which was associated with improved liver enzyme profiles in HIV cohorts.
• Skeletal investigations revealed that Ipamorelin effectively increased bone mineral content and counteracted glucocorticoid-induced decreases in bone formation in adult rat models.
• Tissue remodeling studies highlighted that Tesamorelin administration led to measurable decreases in muscle fat alongside increased muscle cross-sectional area.
• Rodent models of postoperative ileus demonstrated that the selective ghrelin mimetic properties of Ipamorelin significantly improved gastrointestinal motility and transit.

Form & Analytical Testing

• Solid-Phase Peptide Synthesis
• Lyophilization
• Identity Verification: Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the purity standard.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Stanley, T. L., et al. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. The Journal of clinical endocrinology and metabolism, 96(1), 150–158. https://doi.org/10.1210/jc.2010-1587
• Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
• Linda M. Spooner & J. L. Olin. (2012). Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. In Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1Q629
• Fourman, L.T., et al. (2017). Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS, 31, 2253–2259.
• Venkova, K., et al. (2009). Efficacy of Ipamorelin, a Novel Ghrelin Mimetic, in a Rodent Model of Postoperative Ileus. Journal of Pharmacology and Experimental Therapeutics, 329, 1110 – 1116. https://doi.org/10.1124/jpet.108.149211
• Adrian, S., et al. (2018). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. The Journal of Frailty & Aging, 8, 154-159. https://doi.org/10.14283/jfa.2018.45
• Andersen, N. B., et al. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 11(5), 266–272. https://doi.org/10.1054/ghir.2001.0239
• Svensson, J., et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of endocrinology, 165(3), 569–577. https://doi.org/10.1677/joe.0.1650569

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.